drugset
drugset / Trial / NCT03739541

Benznidazole Absorption, Metabolism and Excretion Study

NCT03739541 ↗

Phase 1 Completed 6 enrolled Exeltis France Insud Pharma · collab
NaSingle-groupOpen-labelBasic science

Summary

This Phase I ADME study will be conducted to evaluate the pharmacokinetics of benznidazole.

Timeline

Start
2018-07-16
Primary completion
2018-09-02
Completion
2018-09-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Benznidazole Small molecule 7.4 mbq Oral
Subject Benznidazole Small molecule 100 mg Oral

Indications

No indication recorded.